Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Potential of PARP inhibitors for metastatic breast cancer

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.19
Views: 2303

Dr Alexandra Zimmer - National Cancer Institute, Bethesda, USA

Dr Alexandra Zimmer speaks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about ongoing clinical trials using PARP inhibitors for the treatment of metastatic breast cancer and brain metastases.

She explains that the main challenge with regards to the use of PARP inhibitors is identifying which patient populations responds best to each drug. She also discusses the potential of combination approaches.

Dr Zimmer concludes by speaking about some of the results she looking forward to during the rest of the meeting.

This programme has been supported by an unrestricted educational grant from Pfizer.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation